Caliway Biopharmaceuticals Co. L
6919
주식 순위
#4342
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
주가
$2.29
시가총액
$3.56B
변동 (1일)
-2.50%
변동 (1년)
-57.22%
국가
TW
거래 Caliway Biopharmaceuticals Co. L (6919)
카테고리
Healthcare
Caliway Biopharmaceuticals Co. L (6919)의 주가 이력
최고 종가: $2.44 (2026-10-01 기준)
최저 종가: $0.20 (2022-12-01 기준)
최저 종가: $0.20 (2022-12-01 기준)
Caliway Biopharmaceuticals Co. L의 주가 이력 (2022 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -25.32% |
| 2025 | 190.26% |
| 2024 | 181.33% |
| 2023 | 210.73% |
| 2022 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
